157 related articles for article (PubMed ID: 9713502)
1. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
Caffrey PB; Frenkel GD
Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
[TBL] [Abstract][Full Text] [Related]
2. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
3. Prevention of the development of melphalan resistance in vitro by selenite.
Caffrey PB; Zhu M; Frenkel GD
Biol Trace Elem Res; 1998 Dec; 65(3):187-95. PubMed ID: 9892492
[TBL] [Abstract][Full Text] [Related]
4. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
5. Selenite enhances and prolongs the efficacy of cisplatin treatment of human ovarian tumor xenografts.
Caffrey PB; Frenkel GD
In Vivo; 2012; 26(4):549-52. PubMed ID: 22773566
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of melphalan-resistant tumors to selenite in vivo.
Caffrey PB; Frenkel GD
Cancer Lett; 1997 Dec; 121(2):177-80. PubMed ID: 9570356
[TBL] [Abstract][Full Text] [Related]
7. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo.
Caffrey PB; Frenkel GD
Cancer Chemother Pharmacol; 2000; 46(1):74-8. PubMed ID: 10912582
[TBL] [Abstract][Full Text] [Related]
8. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
Ozols RF; Masuda H; Hamilton TC
NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect.
Silver DF; Piver MS
Gynecol Oncol; 1999 May; 73(2):280-4. PubMed ID: 10329047
[TBL] [Abstract][Full Text] [Related]
14. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
Wang W; Liu G; Zheng J
Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
[TBL] [Abstract][Full Text] [Related]
15. Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite.
Caffrey PB; Frenkel GD
Anticancer Res; 2013 Oct; 33(10):4249-54. PubMed ID: 24122988
[TBL] [Abstract][Full Text] [Related]
16. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease.
Masazza G; Lucchini V; Tomasoni A; Peccatori F; Lampasona V; Giudici G; Mangioni C; Biondi A; Giavazzi R
Cancer Res; 1991 Dec; 51(23 Pt 1):6358-62. PubMed ID: 1933898
[TBL] [Abstract][Full Text] [Related]
17. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
[TBL] [Abstract][Full Text] [Related]
18. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]